Ventas (VTR) Expected to Post Quarterly Earnings on Wednesday

Ventas (NYSE:VTR) is expected to post its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Ventas to post earnings of $0.1423 per share and revenue of $1.68 billion for the quarter. Ventas has set its FY 2026 guidance at 3.820-3.890 EPS. Investors can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 10:00 AM ET.

Ventas (NYSE:VTR) last issued its earnings results on Monday, April 27th. The real estate investment trust reported $0.11 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.01). Ventas had a return on equity of 2.09% and a net margin of 4.25%.The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.59 billion. During the same quarter in the previous year, the firm posted $0.84 earnings per share. Ventas’s revenue for the quarter was up 22.0% on a year-over-year basis. On average, analysts expect Ventas to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Ventas Stock Performance

NYSE:VTR opened at $97.55 on Wednesday. The company has a quick ratio of 0.25, a current ratio of 0.25 and a debt-to-equity ratio of 0.95. Ventas has a fifty-two week low of $65.15 and a fifty-two week high of $97.64. The stock has a market cap of $47.43 billion, a PE ratio of 177.37, a price-to-earnings-growth ratio of 2.07 and a beta of 0.70. The firm’s fifty day simple moving average is $87.62 and its 200-day simple moving average is $84.45.

Ventas Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, July 16th. Investors of record on Tuesday, June 30th were paid a $0.52 dividend. The ex-dividend date was Tuesday, June 30th. This represents a $2.08 annualized dividend and a dividend yield of 2.1%. Ventas’s dividend payout ratio (DPR) is 378.18%.

Wall Street Analyst Weigh In

VTR has been the topic of a number of research analyst reports. UBS Group boosted their price objective on shares of Ventas from $85.00 to $93.00 and gave the stock a “neutral” rating in a report on Monday, May 4th. KeyCorp increased their target price on shares of Ventas from $90.00 to $95.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Jefferies Financial Group lifted their price target on shares of Ventas from $97.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Citigroup boosted their price target on Ventas from $96.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Finally, Mizuho set a $98.00 price target on Ventas in a report on Friday, May 22nd. Fourteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Ventas currently has an average rating of “Moderate Buy” and a consensus target price of $96.17.

Insider Buying and Selling at Ventas

In related news, Director Michael J. Embler acquired 2,500 shares of Ventas stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average cost of $78.81 per share, for a total transaction of $197,025.00. Following the completion of the transaction, the director directly owned 19,202 shares of the company’s stock, valued at $1,513,309.62. The trade was a 14.97% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Walter C. Rakowich sold 1,152 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $90.20, for a total value of $103,910.40. Following the sale, the director directly owned 28,349 shares in the company, valued at approximately $2,557,079.80. The trade was a 3.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.53% of the company’s stock.

Institutional Trading of Ventas

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VTR. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Ventas by 32,509.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 4,648,776 shares of the real estate investment trust’s stock valued at $359,722,000 after purchasing an additional 4,634,520 shares during the last quarter. UBS Group AG boosted its stake in shares of Ventas by 142.4% during the 3rd quarter. UBS Group AG now owns 3,507,841 shares of the real estate investment trust’s stock worth $245,514,000 after purchasing an additional 2,060,770 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Ventas by 27.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,176,254 shares of the real estate investment trust’s stock worth $710,060,000 after buying an additional 2,000,341 shares in the last quarter. Morgan Stanley grew its holdings in shares of Ventas by 19.9% during the fourth quarter. Morgan Stanley now owns 6,344,347 shares of the real estate investment trust’s stock worth $490,926,000 after buying an additional 1,051,836 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Ventas by 21.5% during the third quarter. Invesco Ltd. now owns 5,847,604 shares of the real estate investment trust’s stock worth $409,274,000 after buying an additional 1,034,634 shares in the last quarter. Hedge funds and other institutional investors own 94.18% of the company’s stock.

Ventas Company Profile

Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas’ business model combines property ownership with active asset management and capital markets activity.